420 Lexington Avenue
Suite 350
New York, New York 10170
Telephone: 1.212.584.4180

T Regulatory Cell Program

Rebalancing the Immune System

NeoStem  is collaborating with Becton-Dickinson and the University of California, San Francisco (UCSF) on our T Regulatory Cell program to pursue the development of cell therapies using a person’s immune cells as a therapeutic product to treat disorders of the immune system.

Many immune-mediated diseases are a result of an imbalance in the immune system whereby inflammatory cells go unchecked. Therapy using T regulatory cells (Tregs) represents a novel approach to restoring immune balance by enhancing Treg cell number and function to inhibit pathogenic immune responses.

Download NeoStem’s Treg Program Investor Summary and Article Packet.

T reg

NeoStem - Cell Therapy Development - Clinical